Health Professional Radio - Podcast

Returning guest, Dr. Steve Marcus, CEO of Cantex Pharmaceuticals , a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses Azeliragon and the launch of investigator-led clinical studies focusing on a combination with radiosurgery in patients with brain meta...

Dr. Michael R. Jaff, Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific and Dr. Peter Monteleone, MD, FACC, FSCAI an interventional cardiologist and vascular medicine physician at Ascension Texas Cardiovascular in Austin, Texas and principal investigator of the REAL-PE study talk about the study results and the potential for real-world data to improve patient c...

David Berman, Head of Research and Development at Immunocore discusses the 3-year overall survival data from the  KIMMTRAK Phase 3 trial that  was presented at the European Society of Medical Oncology (ESMO) 2023  for their FDA approved treatment for uveal melanoma, a very deadly type of cancer in the eye. It was the first-ever approved treatment in the space. #Immunocore Dr. David Berman is Head...

Joan Lau, Ph. D., MBA, CEO of Spirovant Sciences discusses cystic fibrosis (CF) and how the standard of care right now addresses but does not correct the underlying cause of the disease. She talks about what needs to be done, and how her organization is working to revolutionize treatment for people living with CF by directly targeting and correcting the underlying cause of the disease. #SpirovantS...

Dr. Lishan Aklog, MD, Chairman and CEO of Lucid Diagnostics , a commercial-stage cancer prevention diagnostics company, discusses the company’s EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device, the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer, targ...

Dr. Mary McGowan, MD, Chief Medical Officer at the Family Heart Foundation , discusses a recent study that revealed concerning findings showing the diagnosis and treatment of a rare genetic disorder, homozygous familial hypercholesterolemia (HoFH), is dangerously underdiagnosed and undertreated. Results published in the Journal of the American Heart Association (JAHA) by the Family Heart Foundatio...

Jeremiah Robison, Founder and CEO of CIONIC discusses the company's success with the FDA-Cleared Cionic Neural Sleeve, the first bionic clothing to combine sensing, analysis, and augmentation to help individuals with neurological conditions like multiple sclerosis, stroke, and cerebral palsy live more freely and independently. CIONIC is now licensed to ship to over 90% of US states (and growin...

Dr. Charles Vega, MD, Family Medicine Specialist and Director of Irvine’s Program in Medical Education for the Latino Community discusses Boehringer Ingelheim and Lilly’s launch of It Takes 2, a new health initiative to elevate the importance of complete testing and early diagnosis of kidney disease, particularly among those who have type 2 diabetes or high blood pressure and are at greater risk f...

Dr. Michael Boland, MD, PhD, Site Director, Mass Eye and Ear , Lexington, Medical Director, Practice Innovation for Ophthalmology, Massachusetts Eye and Ear and Associate Professor of Ophthalmology, Harvard Medical School discusses presentations from the 2023 American Academy of Ophthalmology annual meeting regarding AI and glaucoma. #AAO2023 #AI #glaucoma Dr. Boland is a member of the Glaucoma Se...

Dr. Terence Rooney, Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shares new data that was presented from the Phase 2a IRIS proof-of-concept study, demonstrating the efficacy and safety of nipocalimab in the first-ever clinical study of an FcRn inhibitor in adults living with moderate to severe rheumatoid arth...

Dr. Arlene Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX discusses her presentation at ESMO 2023, abstracts #2362MO and #2359O on Erdafitinib (erda) from the Phase 3 THOR study. For more information visit: https://www.annalsofoncology.org/article/S0923-7534(23)04015-2/fulltext a...

Dr. Nicolas Girard, Professor of Respiratory Medicine at Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute discusses his presentation at ESMO 2023 - Presidential Symposium / Abstract #LBA5 - Amivantamab plus carboplatin/pemetrexed vs carboplatin/pemetrexed as first line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): prim...

Dr. Kim Chi, Senior Research Scientist, Vancouver Prostate Centre discusses his presentation at ESMO 2023, abstract #LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of...

Wensheng Fan, CEO and co-founder of Spectral AI , a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract. This contract is for the advanced development of the DeepView  System, the Company’s AI-driven burn wound imaging technology, to be use...

Voyce is a technology-driven company dedicated to breaking down language barriers in healthcare. CEO of Voyce , Andrew Royce, discusses how the company delivers simple, seamless, and secure on-demand medical interpretation in more than 240 languages and dialects, 24/7. The app is designed to work with smartphones, tablets, laptops, desktops, iOS, Android, Telephonic and APIs. It is easily integrat...

Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial, which showed treatment with tisotumab vedotin demonstrated statistically significant and clinically meaningful overall survival, progression-free survival, and obje...

Jeff Hackman, CEO of Comera Life Sciences, discusses how the company uses its proprietary SQore™ viscosity reduction platform to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. High viscosity is a significant hurdle to formulating subcutaneous biologics and Comera’s addition of excipients, such as caffeine, interrupts intermo...

Dr. ​Jeffrey Popma​, MD, Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic discusses Medtronic’s recent CE Mark approval for the Evolut™ FX TAVI System and the increased need for solutions for patients with symptomatic severe aortic stenosis. #Medtronics #Hearthealth Jeffrey Popma, MD, is the Vice President and Chief Medical Officer for Cor...

Dr. Joe Kimura, Chief Medical Officer, discusses how Somatus deployed a robust transitions-of-care (TOC) service to help their patients safely transition from acute inpatient care to home. Somatus provides TOC services to CKD3/4/5 and ESKD patients and has found patients in the program are 49% less likely to be re-admitted to the hospital compared to usual care.    #Health #Healthcare #Kidneycare...

Dr. Thomas Carroll , Director at Brigham and Women's Voice Program and the Medical Director of Otolaryngology Clinics at Brigham and Women's Hospital discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference, hot topics, and current challenges in the field of ENT. #AAOHNS #Brigham&Womens Dr. Thomas Carroll is the Director at Brigham and Women's...

Wendy Vogel, executive director of the Advanced Practitioner Society for Hematology and Oncology (APSHO) discusses the Make It HAPPen™ campaign and the recent survey that validated the impact APPs have on multiple myeloma patient journeys as well as the need to provide APPs with further educational resources. #MakeItHappen #APPs #APSHO Wendy H. Vogel, MSN, FNP, AOCNP ®, Harborside Executive Direct...

Dr. Dan Faden , Specialist and Investigator in Head and Neck Surgery at Massachusetts General Brigham Mass Eye & Ear discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference titled Ten Hot Topics in Head and Neck Surgical Oncology Panel and Great Debates: ctDNA: Is It Ready for Prime Time? #AAOHNS #HeadAndNeckSurgery #MassGeneralBrigham Dr. Dan Faden is a...

Dr. Khaldoun Tarakji, Vice President and Chief Medical Officer​​ of the Cardiac Ablation Solutions (CAS) Operating Unit (OU) at Medtronic discusses signs and symptoms of AFib and the latest innova​​tions and advancements related to AFib. #AtrialFibrillationAwareness Tarakji, MD, MPH, is the chief medical officer (CMO) of the Cardiac AblationDr. Khaldoun Tarakji, Vice President and Chief Medical Of...

Dave Hering, CEO of  Invivyd, Inc , a biopharmaceutical company discusses the development of a monoclonal antibody to prevent COVID-19 in immunocompromised people, through their pivotal Phase 3 trial called CANOPY.    This is the final step in a rapid development program for an antibody infusion to prevent symptomatic COVID-19 in vulnerable populations. #mAb #COVID19 #immunocompromised Dave Hering...

Dr. Susan MacDonald, MD, board-certified ophthalmologist, Co-founder and CEO of Eye Corps discusses Eye Corps' mission to eliminate preventable blindness in sub-Saharan Africa through strategic partnerships with the local medical community and ophthalmic training institutions. Eye Corps works to build a sustainable infrastructure for eye care delivery in sub-Saharan Africa with a focus on elim...